Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Frederick W Driscoll is Director at Lite Strategy. OQRO lists 3 transactions filed with the SEC under this name, the latest on Oct 26, 2026, each linked to the official Form 4.
Director
Disclosures on record
3
Companies involved
2
Lite StrategyLITS
2 disclosures · Nov 2025 – Oct 2026
Oct 22, 2026100Kdisclosed Oct 26
DetailsOfficial recordNov 14, 202555Kdisclosed Nov 18
DetailsOfficial recordJul 7, 202625Kdisclosed Jul 9
DetailsOfficial recordFrederick W Driscoll bought shares on the open market in 2011, 2019 and 2021, and has not bought since 2021 across 4 companies. Sales in 2 of the 16 years since 2011.
Frederick W Driscoll reported 3 open-market purchases and 4 sales since 2011; purchases in 3 different years, most recently 2021.
| Year | Bought | Sold |
|---|---|---|
| 2021 | $20K1×1 trade | $101K1×1 trade |
| 2020 | — | $668K3×3 trades |
| 2019 | $100K1×1 trade | — |
| 2011 | $24K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Frederick W Driscoll bought shares on the open market in 2011, 2019 and 2021, and has not bought since 2021 across 4 companies. Sales in 2 of the 16 years since 2011.
In SEC filings since 2011: the latest open-market purchase is from 2021; the latest open-market sale is from 2021.
4 companies: Lite Strategy (LITS, 2019–2021), Cellectar Biosciences (CLRB, 2021), Immunitybio (IBRX, 2020), Novavax (NVAX, 2011).
Frederick W Driscoll reported 0 open-market purchases and 3 sales here, 2020.
Frederick W Driscoll reported 1 open-market purchase and 1 sale here, 2019 to 2021.
Frederick W Driscoll reported 1 open-market purchase and 0 sales here, 2021.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.